Triptorelin for the treatment of endometriosis

Umberto Leone Roberti Maggiore, Carolina Scala, Valentino Remorgida, Pier Luigi Venturini, Fabio Del Deo, Marco Torella, Nicola Colacurci, Stefano Salvatore, Stefano Ferrari, Enrico Papaleo, Massimo Candiani, Simone Ferrero

Research output: Contribution to journalArticlepeer-review


Introduction: Over the past 30 years, gonadotropin-releasing hormone agonists (GnRH-a) have been used to induce a hypoestrogenic status in women with endometriosis with the aim to cause an improvement in pain symptoms similar to that observed after menopause. Triptorelin is one of the most commonly used GnRH-a. Areas covered: This review offers an explanation of the mechanism of action, of the pharmacokinetics and pharmacodynamics of triptorelin and gives the readers a complete overview of the studies on the clinical efficacy, tolerability and safety of this agent in patients with endometriosis. Expert opinion: The studies reviewed in the current manuscript demonstrate the efficacy of triptorelin in improving pain symptoms caused by endometriosis. Further, this effect is confirmed by the reduction in the volume of the endometriotic nodules during treatment. Future research should evaluate whether the pre-operative administration of triptorelin prior to surgical excision of endometriomas may be useful in preserving the ovarian reserve.

Original languageEnglish
Pages (from-to)1153-1179
Number of pages27
JournalExpert Opinion on Pharmacotherapy
Issue number8
Publication statusPublished - 2014


  • Efficacy
  • Endometriosis
  • Gonadotropin-releasing hormone analogue
  • Safety
  • Triptorelin

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology
  • Medicine(all)


Dive into the research topics of 'Triptorelin for the treatment of endometriosis'. Together they form a unique fingerprint.

Cite this